Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by aliasunknownon Mar 27, 2018 6:12pm

73 Views

Post# 27790487

RE:forget antibe ...heal ulcers quickly especiall microscopic o

Hugeopp you inbred trailer trash hillbilly. Atb 346 is not about healing ulcers. Do your home remedies relieve arthritic pain? Damn you're as dumb as the day is long. It's about pain relief with minimal ulceration compared to naproxin,. 42% with naproxin 2.5% atb346. A partner is in talks with Antibe and will be announced when an agreement is made.

Bullboard Posts

Global Tungsten Market and Supply Security